熱門資訊> 正文
Dexcom入选FDA数字医疗服务试点第一家公司
2026-07-23 05:39
- 德康醫療(DXCM) 0
- JPMorgan Climate Change Solutions ETF JPMorgan Climate Change Solutions Fund(TEMP) 0
- 德意志銀行(DB) 0
- The US FDA has chosen Dexcom (DXCM) as the first participant in its Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program.
- The continuous glucose monitor maker said it would "implement an AI-powered glucose health program that integrates data from Dexcom G7 and Stelo with contextual health information such as nutrition, physical activity, sleep and stress, to deliver more personalized insights for healthcare professionals and program eligible users."
- TEMPO's purpose is to examine new digital health technologies that work to improve chronic disease management and provide real-world data.
More on Dexcom
- DexCom: The Growth Thesis Still Needs To Be Proven
- DexCom: A Medical Platform Play Gaining From AI, Not Disrupted By It
- DexCom Might Finally Be Cheap Enough
- DexCom, Insulet gain news Buys at Deutsche Bank despite recent selloff
- DexCom's OTC CGM Stelo gains pediatric approval
推薦文章
美股前瞻 | 聯儲局再傳「鷹聲」！美債收益率應聲走高，納指期貨跌近1%；中美第八輪經貿磋商達成多項共識；Meta全面押注個人Agent
一周財經日曆 | 影響加息大事！9月大小非農數據重磅登場；美光、希音齊放榜！景旺電子、歡創科技等5只新股下周上市
Q4淨利或狂飆逾1000%！美光能否交出」炸裂「財報？三大焦點將影響股價走向
休市提醒：中秋假期來臨，港股9月25日（周五）正常開市
華盛早報 | 強勁PMI催高加息預期！納指回調1%；美財政部擬再回購60億美元長債；SpaceX總裁套現逾5200萬美元
美股前瞻 | 特朗普最新調倉曝光！拋售微軟，買入英偉達；Meta科技盛會重磅來襲；高盛、德銀齊看多：標普500將衝刺8000點
特朗普重新定義AI：美國今后將把人工智能稱為「超級智能」
特朗普將亮相聯大：聚焦伊朗 密集會見多國領導人 計劃與丹麥簽署協議
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
